Developing strategies for liver fibrosis treatment
Murphy, Frank, Arthur, Michael and Iredale, John (2002) Developing strategies for liver fibrosis treatment. Expert Opinion on Investigational Drugs, 11, (11), 1575-1585. (doi:10.1517/135437126.96.36.1995).
Full text not available from this repository.
Liver fibrosis represents a major worldwide healthcare burden. Current therapy is limited to removing the causal agent. This approach is successful in some diseases; particularly haemochromatosis and chronic viral hepatitis. However, for many patients treatment is not possible, while other patients present to medical attention at an advanced stage of fibrosis. There is therefore a great need for novel therapies for liver fibrosis. The hepatic stellate cell has been recognised to be responsible for most of the excess extracellular matrix observed in chronic liver fibrosis. The detailed understanding of hepatic stellate cell biology has allowed the rational design of novel antifibrotic therapies. This review describes for the general reader the novel emerging therapies for liver fibrosis.
|Subjects:||R Medicine > R Medicine (General)|
|Divisions:||University Structure - Pre August 2011 > School of Medicine > Infection, Inflammation and Repair
|Date Deposited:||26 Apr 2006|
|Last Modified:||01 Jun 2011 11:23|
|Contributors:||Murphy, Frank (Author)
Arthur, Michael (Author)
Iredale, John (Author)
|RDF:||RDF+N-Triples, RDF+N3, RDF+XML, Browse.|
Actions (login required)